Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275439 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
A Phase 1 study, sponsored by Shattuck Labs.
- Terminated
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT05275439: Clinical Trial Phase 1 study, sponsored by Shattuck Labs.
NCT05275439 is a Phase 1 study that was terminated before completion, run by Shattuck Labs. The registered enrollment target is 106 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05275439, a Phase 1 study, was terminated before completion, sponsored by Shattuck Labs.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.
Primary Outcome
Number of participants with treatment emergent adverse events from dose escalation and dose expansion cohorts
Interventions
- DRUG Venetoclax
- DRUG Azacitidine (AZA)
- DRUG SL-172154
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2025-02-06 |
| Phase | Phase 1 |
Why NCT05275439 stopped before completion
NCT05275439 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% higher).
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT05275439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05275439 about?
NCT05275439 is a clinical study titled "Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML". SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.
What is the current status of trial NCT05275439?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2022-03-17. Estimated completion is 2025-02-06.
What interventions are being tested in trial NCT05275439?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (AZA) (DRUG), SL-172154 (DRUG).
Who is sponsoring clinical trial NCT05275439?
This trial is sponsored by Shattuck Labs, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05275439's enrollment target sits among peer trials
106 531st of 2000 higher than 1,468 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI